Comparison of a standard and a sensitive thromboplastin in monitoring low intensity oral anticoagulant therapy.
The greater precision in prothrombin time monitoring obtained using thromboplastins with low international sensitivity index (ISI) values are believed to result in improved patient care. The authors conducted a blinded prospective study of 84 random patients on low-intensity warfarin therapy who were monitored with either a sensitive (ISI, 1.3) or standard (ISI, 1.9) thromboplastin. For the patients monitored with standard and sensitive thromboplastins, respectively, no difference was found in the degree of anticoagulation (standard thromboplastin mean INR, 2.4 vs. 2.5, P = .37; sensitive thromboplastin mean INR, 2.6 vs. 2.6, P = .74; mean daily warfarin dose, 5.1 vs. 4.7 mg, P = .28) or efficacy (warfarin dosage adjustments, 117 vs. 116; clinic visits, 362 vs. 378; percentage of therapeutic INR determinations, 47% vs. 48%). In addition, no difference was found in bleeding prevalence or severity (.22 vs. .27 events per person-year observation). The authors concluded that monitoring anticoagulant therapy in the INR range of 2-3 with a standard thromboplastin may be comparable to monitoring with a more sensitive thromboplastin with respect to efficacy, safety, and degree of anticoagulation achieved.
Department of Medicine (III), Boston Veterans Affairs Medical Center, MA 02130.
M T
MT
Brophy
L D
LD
Fiore
J
J
Lau
R
R
Goodwin
A
A
Lopez
D
D
Deykin
D000284:Administration, Oral; D000368:Aged; D004311:Double-Blind Method; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011517:Prothrombin Time; D012015:Reference Standards; D013925:Thromboplastin / Q000737:chemistry*; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
D014859:Warfarin; D013925:Thromboplastin